Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell”

Seres Therapeutics (NASDAQ:MCRB) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Wednesday.

A number of other research firms have also commented on MCRB. JPMorgan Chase & Co. lowered shares of Seres Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Thursday, October 24th. Canaccord Genuity Group restated a “buy” rating and issued a $10.00 price target on shares of Seres Therapeutics in a research report on Thursday, November 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Wednesday, November 13th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.08.

Seres Therapeutics Stock Down 0.9 %

Shares of NASDAQ MCRB opened at $0.88 on Wednesday. Seres Therapeutics has a 52-week low of $0.54 and a 52-week high of $2.05. The stock has a market capitalization of $149.74 million, a price-to-earnings ratio of -3.81 and a beta of 2.06. The stock’s fifty day simple moving average is $0.82 and its 200 day simple moving average is $0.90.

Institutional Trading of Seres Therapeutics

A number of hedge funds have recently made changes to their positions in MCRB. Virtu Financial LLC raised its holdings in shares of Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 18,191 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Seres Therapeutics by 22.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company’s stock worth $1,314,000 after purchasing an additional 255,014 shares in the last quarter. State Street Corp raised its stake in shares of Seres Therapeutics by 12.9% during the 3rd quarter. State Street Corp now owns 383,248 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 43,700 shares in the last quarter. Providence Wealth Advisors LLC lifted its holdings in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Seres Therapeutics by 0.6% in the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after buying an additional 140,096 shares in the last quarter. 59.34% of the stock is owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.